ACRV
Acrivon Therapeutics, Inc.
1.90$
+1.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.5% | -12.8% | +91.3% | -6.9% | -8.4% | -10.3% | -10.1% | -8.4% | -10.7% | -16.9% | -8.1% | |
| – | -10.2% | -13.5% | +62.6% | +3.6% | -3.9% | -16.7% | -8.5% | -5.8% | -7.6% | -17.6% | -7.8% | |
| – | +20.6% | -31.7% | +87.0% | -5.6% | -8.3% | -1.7% | +7.0% | -15.5% | +17.2% | -17.9% | +21.6% | |
| – | -10.3% | -13.7% | +64.2% | +3.8% | -4.3% | -16.6% | -8.2% | -5.9% | -8.3% | -17.6% | -8.0% | |
| – | +31.9% | -26.5% | +15.8% | +22.5% | +11.3% | -19.4% | -2.6% | +7.4% | +3.0% | -28.4% | +0.9% | |
| – | +43.1% | -32.0% | +24.8% | +31.3% | +16.2% | -21.3% | -0.9% | +10.9% | +5.2% | -29.4% | +3.6% | |
| – | +13.0% | +7.6% | +3.6% | +6.3% | +1.6% | +4.5% | +3.9% | +3.1% | -1.0% | -1.7% | -1.5% | |
| – | +235.6% | -59.3% | -38.7% | +19.4% | -49.7% | +386.9% | -68.5% | -14.4% | +128.6% | -49.0% | -25.9% | |
| – | -12.3% | -10.9% | +100.1% | -8.9% | -10.2% | -9.3% | -10.8% | -10.1% | -12.5% | -15.1% | -9.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.2% | +1.1% | +59.9% | +5.5% | +0.4% | +0.3% | +0.3% | +0.3% | -0.1% | +0.6% | +8.0% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.